³J¶ÀÁx©T¾J§t¶qªº½Õ±±»P°·±d³J¤§¥Í²£

ºK­n

        Áx©T¾J»P°Ê¯ßµ°¼Ëµw¤Æ¤§Ãö«Y¡Aªø¤[¥H¨Ó«K¨ü¨ì­«µø¡A¬ü°ê¤ßŦ¾Ç·|±ÀÂËÁx©T¾J¤§¨C¤H¨C¤éÄá¨ú¶qÀ³§C©ó300mg¡CÂû³J¨Cªª¬ù§tÁx©~¾J200~250mg¡A³Qµø¬°¬O°ªÁx©T¾J­¹ª«¡A¤H­Ì¦]°·±d·NÃÑ©ïÀY¡A¦Ó¨ÏÂû³Jªº®ø¶O¶qÃø¥H¦A¦¨ªø¡A¦Ó¬°¦]À³¥«³õ»Ý¨D¡A¹E¦³¡u§CÁx©T¾J¶q¡vªº¬ãµo¡C

        ¬ã¨s¤H­û´¿À³¥Î¿ò¶Ç¿ï©Þ¡BÀç¾i©MÃĪ«µ¥¤è¦¡¨Ó±±¨î§Z¶ÀÁx©T¾J§t¶q¡Aµ²ªGµo²{¹}³Áx©T¾J©M¯×ªÕ·|¼W¥[§Z¶ÀÁx©T¾J§t¶q¡A¦Ó¹}³ÅÖºû§t¶q©Î¬Y¨ÇÃĪ«¥i¥H´î§C§Z¶ÀÁx©T¾J§t¶q¡A¦ý­°´T¦³­­¡A§Q¥Î¿ò¶Ç¿ï©Þ«h¨Ã¥¼¨£¦¨®Ä¡A©Î¶È¯à­°§C5-7¢HÁx©T¾J¡A¦P®É²£³Jªí²{¨ü¨ì¼vÅT¡A¬G¥Ø«e¬°¤î«ÜÃø¦¨¥\¦a±N§Z¶ÀÁx©T¾J§t¶q­°§C¡C

        w-3¯×ªÕ»Ä¡A³Q»{¬°¬OÁקK¤ßŦ¦åºÞ¯e¯fªº¦³¥Îª«½è¡A¬G¤HÃþÀç¾i¾Ç®a©MÂå¥Í³£«Øij¤H­ÌÀ³¼W¥[¹ïw-3¯×ªÕ»ÄªºÄá¨ú¡C¥Ø«e¸û´¶¹Mªºw-3¯×ªÕ»Ä¦³EPA¡BDHA©M¨È³Â¤¯ªo»Ä¤TºØ¡A³JÂû¦pÁý¤©°ª¶qªºw-3¯×ªÕ»Ä¡A¨ä³J¶À¤¤¯×ªÕ»Ä¤§²Õ¦¨«Ü®e©ö§ïÅÜ¡Aw-3¯×ªÕ»Ä¤§§t¶q·|©úÅã¼W¥[¡A°·±d³J¤§¥Í²£¤DÀ³¹B¦Ó¥Í¡F¦ýEPA©MDHA¤@¯ë¥H³½ªo©Î³½¯»¤¤§t¶q¸û°ª¡A¨Ï¥Î°ª³½ªo©Î³½¯»¹}³¡A³J¤¤±`·|¦³³½¸{¨ý²£¥Í¡C¨È³Â¬ó§t¦³°ª¶q¤§¨È³Â¤¯ªo»Ä¡A³JÂû¥ç¥i±N°ª¶qªº¨È³Â¤¯ªo»Ä²¾¤J§Z¶À¡A¦ý¨Ï¥Î°ª¶qªº¨È³Â¬ó(30¢H)¡A¹ï³JÂû¦³¤£¨}¤§°Æ§@¥Î¡A¥B³J¥ç·|¦³³½¸{¨ý¡A¬O¥¼¨Ó·¥«Ý§JªAªº¤@¶µ¤u§@¡C

¤@¡B«e¨¥

        ¤ßŦ¯f¬O³\¦h°ê®a¤¤­º­nªº­P¦º¯f¦]¤§¤@¡A¦Ó³y¦¨¤ßŦ¯fªº¤T¤j¦MÀI¦]¯À­p¬°Áx©T¾J¹L°ª¡BªÎ­D©M°ª¦åÀ£¡C¦å²G¤¤ªºÁx©T¾J§t¶q¸gÃÒ¹ê»P«aª¬°Ê¯ß¤ßŦ¯f(coronary heart disease, CHD)¦³Ãö¡A¦]¬°¥¦·|¤Þ°_°Ê¯ßµ°¼Ëµw¤Æ(Atherosclerosis)¡CÁ{§É¸ÕÅç«ü¥X¡A¦åÁx©T¾J§t¶q¨C­°§C1¢H¡A«aª¬°Ê¯ß¤ßŦ¯fªºµo¥Í²v±N·|´î¤Ö2¢H¡A¬G¬ü°ê¤ßŦ¾Ç·|±ÀÂ˨C¤H¨C¤éªºÁx©T¾JÄá¨ú¶qÀ³¤Ö©ó300mg¡A§_«h´NÀ³¸Ó¦hÄá¨ú´I§tw-3¯×ªÕ»Ä¡A¥H´î¤Ö¤ßŦ¯fªº½ÄÀ»¡C¤@ªTÂû³J©Ò§tªºÁx©T¾J¶q¥­§¡¬°200-250mg¡A¥¦³Q¤½»{¬O¤HÃþ¹}³Áx©T¾J³Ì¥D­nªº¨Ó·½¡A¬G¦b¼Ú¡B¬ü¡AÁx©T¾J´N¦¨¤Fªñ¦~¨Ó³J®ø¶O¶q¤U­°ªº¥D­n­ì¦]¡AÁöµM¦]³JÃþ¦Ó¤Þ°_ªº°Ê¯ßµ°¼Ëµw¤Æªº¤ñ²v¦b©Ò¦³±Ú¸s¤¤³£¬Û·í¤Ö¡A¦ý®a¸V·~¬É¤j®a³£±N¥Í²£¡u¦ÛµMªº§CÁx©T¾J³J¡v©Î§t°ª¶qw-3¯×ªÕ»Ä³J(«UºÙ°·±d³J)¡A»{¬°¬O¥¼¨Óªº¥D­n°Ó¾÷¡CµM¦ÓÂû³J¤§Áx©T¾J§t¶q¡A¬O§_¯u¥i¥HÂÇ¿ò¶Ç¿ï©Þ¡BÀç¾i©ÎÃĪ«¨Ó¥[¥H½Õ±±¡H¤S¤j®a©Ò±ý¥Í²£¤§°·±d³J¡A¸Ó¦p¦ó¥Í²£¡H¦³¦ó¯q³B¡H¥»¤å±N¥[¥Hºî¦X±´°Q¡C

¤G¡BÁx©T¾Jªº¥Í²z¥\¯à

        Áx©T¾J¬O¶È¦s©ó°Êª«Å餺¡A¦Ó¤£¦s©ó´Óª«Åé¡A¥ÑAcetyl-CoA¸g¥Ñ¤@³s¦ê¤ÏÀ³©Ò¦X¦¨¡A§t27­ÓºÒ¡A¤À¤l­«¬°386¡A¦b°Êª«Å餺¥D­n¥H´åÂ÷ºA(free cholesterol)©M୤ƺA(cholesterolester)¤GºØ¤è¦¡¦s¦b¡A¤GªÌ¤ñ¨Ò¦]²Õ´¤£¦P¦Ó²§¡A¨ä¦b¤HÅ餤ªº¦X¦¨¥D­n¦ì¸m¬°¨xŦ(¦û50¢H)¡B¤p¸z(¦û15¢H)¡B¨ä¥L²Õ´(¥H¥Ö½§³Ì¦h¡A¦û35¢H)¡F¦Ó¦b³JÂû¨ä³Ì¥D­n¦ì¸m¬°¨xŦ¡A¦Ó§Z±_«h¥u¦³·¥·L©Î¬Æ¦Ü¨S¦³¯à¤O¥h¦X¦¨¯×³J¥Õ(Griffin, 1993)¡C¤HÅé¤Î°Êª«§¡»Ý­n¤@¨ÇÁx©T¾J¡A¥H«Kºû«ù¥Í©R¤Î¥¿±`¥Í²z¥\¯à¡CÁx©T¾J¦b°Êª«Å骺¥Í²z¥\¯à¦³(1)¥¦¬O²Ó­M½¤ªº¥²¶·¦¨¥÷¡A¥i½Õ¸`²Ó­M½¤ªº¬y°Ê©Ê¡A(2)Áx©T¾J¬Oºû¥Í¯ÀD¡BÁx»Ä©MÃþ©T¾J¤ºªc¯Àªº¥ý½è¡A(3)¬O­F­Lµo¨|©Ò»Ýªºª«½è¡A¦b¦ÛµM¿ï©ÞÀ£¤O(Natural selection pressure)¤U¡A¬°ºû«ù­F­Lµo¨|ªºÀç¾iÀô¹Ò¡A¬G³y¦¨¿ò¶Ç¿ï©ÞµLªkÅãµÛ­°§C³J¤¤¤§Áx©T¾J§t¶q(Holland et al., 1980)¡CÁx©T¾J¦b³JÂûÅ餺¤§¥­¿Å(¹Ï3)¡A¥D­n¨ú¨M©ó§ë¤J»P²£¥X¶q¤§¶¡ªº¥­¿Å¡A·í³JÂûÄá¨ú°ª¶qªºÁx©T¾J®É¡A¬°ºû«ù¨ä¦å¤¤¥¿±`ªºÁx©T¾J¿@«×¡A³o®É±NÁx©T¾J±Æ°£¨ìÂû³J¤º¡A´N¦¨¬°¤@ºØ¬Û·í¦³®Äªº¤è¦¡(Hargis, 1988)¡C

wpe182.jpg (22959 bytes)

¤T¡BÂû§Z¶Àªº²Õ¦¨

        (¤@)Âû§Z¶Àªº²Õ¦¨

        §Z¶Àªº²Õ¦¨(ªí1)¡A¦³95¢Hªº§Z¶ÀÁx©T¾J¬O¦s¦b©ó´I§t¤T»Ä¥Ìªo¯×ªº¯×³J¥Õ(TG-rich lipoprotein, VLDL)¤¤¡A¨ä¾l5¢H«h»P¯×§Z¶ÀÁC³J¥Õ(lipovitellin)µ²¦X(Griffin, 1993)¡C§Z¶ÀÁx©T¾J¤¤¡A¬ù¦³20¢H¬O¥HÁx©T¾Jà­(cholesterol ester)¤è¦¡¦s¦b(Noble, 1987)¡A¨ä¾l80¢H«h¬°´åÂ÷Áx©T¾J(free cholesterol)¡C¦b½Õ±±§Z¶ÀÁx©T¾J®É¡A¤@¯ë¸û©ö§ïÅܨäÁx©T¾Jà­§t¶q¡A¦ý´åÂ÷Áx©T¾J§t¶q«h¤£®e©ö§ïÅÜ(Hargis, 1980)¡C

ªí1. §Z¶Àªº²Õ¦¨

¶µ¥Ø ¦Ê¤À¤ñ(¢H)
¤ô¥÷

¯×ªÕ

³J¥Õ½è

Äqª«½è

48

33

17

1

¥D­n¦¨¥÷¡G

(1)´I§t¤T»Ä¥Ìªo¯×ªº¯×³J¥Õ(VLDL).(2)¯×§Z¶ÀÁC³J¥Õ(3)ÁC³J¥Õ

¦¸­n¦¨¥÷¡G

(1)§K¬Ì²y³J¥Õ(2)¦å²M¥Õ³J¥Õ(3)ºû¥Í¯ÀB1¡BB2©M¥Íª«¯ÀªºÄâ±a³J¥Õ½è¡C

        (¤G)§Z¶Àªº§Î¦¨

        Âû°¦ªº§Z±_¥u¦³·¥§C©Î¬Æ¦Ü¨S¦³¯à¤O¥h¦X¦¨¯×½è¡A©Ò¥H´X¥G©Ò¦³ªº§Z¶À¯×³J¥Õ¥ý½è³£¬O¥Ñ¨xŦ©Ò§Î¦¨¡AµM«á¸g¥Ñ¦å²G¿é°e¨ì§Z±_Âoªw¡A¦Ó¥H±µ¨üÅ鬰´C¤¶¤§²Ó­M¤º¾½¤è¦¡(receptormediated endocytosis)¶i¤J§Z¥À²Ó­M¤º¨I¿n¦Ó§Î¦¨§Z¶À¡C¥ÀÂû¦bªì²£¤§«e¡A¨ä¦å¼ß¤¤¤§¯×½è¿@«×ÆJµMªº¼W¥[¡A¥D­n¬O¦]¬°·¥§C±K«×¯×³J¥Õ(very low density lipoprotein, VLDL)¤ÎVitellogenin(VTG)¨âºØ¥D­n§Z¶À¥ý½èªº´`Àô²Ö¿n©Ò­P¡C²£³JÂû¦å¼ß¤ºªºVLDL»P¥¼¦¨¼ô¥À½Þ©Î¤½Âû¦³·¥¤jªº®t§O(Griffin and Hermier, 1988)¡A¥¦­Ìªºª½®|³q±`«Ü¤p(20~25mm)¡A¦Ó¥B¤j¤p«Ü¾ã»ô¡A¥u§t¦³apo-£]©Mapo-VLDL-¢º¤GºØ¥D­n²æ»²°ò³J¥Õ(apoprotein)¡C²£³J®a¸VªºVLDL¬O¨ä¥L®a¸V©Ò¯Ê¥F¡Aapo-VLDL-¢º»P­÷¨ÅÃþ°Êª«©Ò¨ã¦³¤§apo-C-¢º§@¥Î¬Û¤Ï¡A¥i¥H§í¨î¯×³J¥Õ¸Ñ¯×ú@(lipoprotein lipase)ªº¸Ñ¯×§@¥Î(Griffin, 1993)¡C¦³«Ü¦h¸ÕÅçÅã¥Ü¡AVLDLªº¤j¤p¦pªG·U¤p¡A¨ä¹ïÁx©T¾Jªº¿Ë©M©Ê(affinity)·U°ª¡F²£³JÂû¦]¬°¦å¼ß¯×³J¥Õ¤p¡A©Ò¥H®e©ö³q¹LÂoªw¾Àªº°ò©³¼h¡A¯×³J¥Õ¦]¥i§¹¾ã¦a¶i¤J§Z¥À²Ó­M¤º¡A©Ò¥H§Z¶ÀÁx©T¾Jªº§t¶q¡A¨M©w©ó­Ó§O¯×³J¥Õ²É¤lªºÁx©T¾J¶q¡CVitelloginin¥u¥X²{©ó²£³J®a¸V©Î¸g¥Ñ°Ê±¡¯À³B²z¤§³¾Ãþ¡A¥¦¬O§Z¶ÀªºÁC³J¥Õ(phosvitin)©M¯×§Z¶ÀÁC³J¥Õ(lipovitellin)ªº¥ý½è¡A¨ä¤À¤l¶q¬ù450KDa¡A§t¦³¬ù20¢H¯×½è¡A¬O²£³J®a¸V¦å²G¤¤ªº¥D­nÄâ¶t³J¥Õ½è(calcium binding protein)¡A¨ä20¢H¯×½è¤¤¥D­nªº¦¨¥÷¬OÁC¯×½è(phospholipid)©MÁx©T¾J¡A¬OÄÝ©ó·¥°ª±K«×¯×³J¥Õ(very high density lipoprotein, VHDL)¡CVLDL©MVitelloginin­n¶i¤J§Z¥À²Ó­M®É¡A¦b§Z¥À²Ó­M½¤¤W¥u¦³¤@ºØ±µ¨üÅé¡A¥sVLDL¡þVTG±µ¨üÅé(VLDL¡þVTG receptor)¡AVLDL¡þVTG±µ¨üÅé¥D­n¬O¸g¥Ñ¿ë»{VLDL¤Wªºapo-£]Vitelloginin¤Wªº¯×§Z¶ÀÁC³J¥Õ(lipovitellin)¡F¦b¬¡Åé¥~¸ÕÅçÅã¥Ü¡AVLDL©MVitelloginin´N¸g¥ÑVLDL¡þVTG±µ¨üÅ鬰´C¤¶ªº²Ó­M¤º¾½§@¥Î¡A¦Ó¶i¤J§Z¥À²Ó­M¤¤¡C¦b¬Y¨Ç¬ðÅܦӤ£¯à±Æ§Zªº³JÂû«~¨t¡A¦]¬°¨e­Ì¨ã¦³ªº¿ò¶Ç°ª¦å¯×¯g(hereditary hyperlipidaemia)¦ÓµLªk²£³J¡A¨ä§Z¥À²Ó­M½¤¤W´N¯Ê¥FVLDL¡þVTG±µ¨üÅé¡C

¥|¡BÂû§Z¶ÀÁx©T¾J§t¶q¤§±±¨î¤èªk¤Î®ÄªG

        (¤@)¿ò¶Ç¿ï©Þ(genetic selection)

        Holland et al., (1980)¦b1967~1972¦~¶¡¡A±N¥Õ¦â¨Ó¯èÂû¨Ì¦å¼ßÁx©T¾J¿@«×¤À¬°°ª¡B§C©M¥¼¿ï©Þ¤T²Õ¡A¸g¤­¥Nªº¿ï©Þ¡Aµ²ªG(ªí2)Åã¥Ü¦b§C¦å²GÁx©T¾J²Õ¡A¨ä§Z¶À¤§Áx©T¾J¶qÅãµÛ¤U­°¤F7.8¢H¡A¦Ó°ª¦å²GÁx©T¾J²Õªº§Z¶ÀÁx©T¾J§t¶q«hµL©úÅãÅÜ¡F§C¦å²GÁx©T¾J²Õªº§Z¶ÀÁx©T¾J¶qÁö©úÅã¤U­°7.8¢H¡A¦ý¦b¹ê»ÚÀ³¥Î¤W¤´¤£ºâÅãµÛ¡A¦p»P¨C¤é300mg±ÀÂ˶q¬Û¸û¡A250mg¡Ñ7.8¢H¡×19.5mg¡F¨ä§@¥Î¤£¤j¡CAnash et al., (1985)¨Ì§Z¶À¤§Áx©T¾J§t¶q±N³JÂû¤À¬°¹ï·Ó¤Î¿ï©Þ¨â²Õ¡A¶i¦æ§CÁx©T¾J³JÂû¤§¿ï©Þ¡A¸g¤T¥Nªº¿ï©Þ¡A²Ä¤T¥NªºÂû°¦¡A¨ä§Z¶ÀÁx©T¾J¶È¤U­°¤F5.4¢H¡A¦ý³J­«¥ç¬Û¹ï¦a¤U­°¤F1~2g¡CMarks and Washburn(1977)§Q¥ÎÂù¦V¿ï©Þ¡A¹ï¦×ºØÂû©M³JÂû¶i¦æ¥|¥N©M¤T¥Nªº¿ï©Þ¡Aµ²ªG(ªí3)ÃÒ©ú¡A¿ï©Þ½T¹ê¦³®Ä¡A¦ý¶È­­©ó¦V¤W¿ï©Þ(upward direction)¡A¦V¤U¿ï©Þ«h®ÄªG¦³­­¡A¨ä¸ÑÄÀ»PAndrews et al., (1968)¦]­F­Lµo¨|»Ý­nÁx©T¾J¤§»¡ªk¬Û¦P¡C

ªí2. ¸g¤­¥N¿ï©Þ«á³JÂû¤§¦å¼ß©M§Z¶ÀÁx©T¾J§t¶qªí

¡@ ¥¼¿ï©Þ §CÁx©T¾J²Õ °ªÁx©T¾J²Õ
Âû°¦¼Æ¥Ø 87 79 69
¥­§¡­È±¼Ð·Ç°¾®t

§Z¶Àa

¦å²Gb

¡@

1387±12

97±1.2

¡@

1279±9

69±0.8

¡@

1373±11

135±1.5

¬ÛÃö

§Z¶À¡þ¦å²G

¡@

0.04

¡@

0.04

¡@

-0.08

a. 60¶gÄ֮ɱļË

b. 9~10¶gÄÖ®É±Ä¼Ë                                                                                                                ºK¦Û¡GHolland et al., 1980

ªí3. ¤£¦P¥N¸¹¤§¿ï©Þ«~¨t»P¹ï·Ó«~¨tªºÁx©T¾J¥­§¡­È©M¼Ð·Ç°¾®t1

«~ºØ ¥N¼Æ ¦~ §CÁx©T¾J¨t(L) °ªÁx©T¾J¨t(H) ®t²§(H¡ÐL) ¹ï·Ó²Õ
¦×ºØÂû

¡@

¡@

¡@

S1

S2

S3

S4

1972

1973

1974

1975

17.97±2.42

17.07±1.62

18.30±3.29

18.90±1.68

18.53±3.21

18.12±1.98

19.04±2.12

20.17±1.58

0.59

1.05

0.75

1.27

¢w

18.13±2.06

17.43±2.01

19.00±1.60

¨Ó¯èÂû

¡@

¡@

S1

S2

S3

1973

1974

1975

16.34±1.45

17.03±1.57

17.56±3.21

16.93±1.66

18.09±2.46

18.94±2.19

0.59

1.06

1.38

17.48±1.68

17.04±2.80

17.15±1.89

µù¡G1. Áx©T¾Jmg¡þg§Z¶À                                                                                         ºK¦Û¡GMarks and Washburn(1977)

        1. Áx©T¾Jmg¼Æ¡þg§Z¶À

        Ali(1977)ÃÒ©ú³J¶À©M¦å²G¤§Áx©T¾J§t¶q¥D­n¨ü¨ì«D¥[­¼©Ê°ò¦](nonadditive gene)ªº§@¥Î¡A¦P®É¥L¤]«ü¥X¡A²£³J²v©M§Z¶À¤§Áx©T¾J§t¶q¶¡§e­t¬ÛÃö¡A¦¹µ²ªG»PBartov et al., (1971)¤§µ²ªG¬Û¤@­P¡CCunningham et al., (1974)«ü¥X¦b¥L­Ì©Ò¿ï©ÞªºÂû¸s¸Ì¡A§Z¶ÀªºÁx©T¾J§t¶q»P¹å¤Æ²v¶¡¦³ÅãµÛ¬ÛÃö¡A¦ýWashburn and Marks(1977)«h«ü¥X¦b°ª©Î§CÁx©T¾J¿ï©Þ²Õ¡A¨ä§Z¶ÀÁx©T¾J§t¶q¹ï¹å¤Æ²vªº¼vÅT¤£ÅãµÛ¡F¦ý§Z¶ÀÁx©T¾J§t¶q»P²£³J¼Æ§e­t¬ÛÃö¡A¤£½×°ª¡B§CÁx©T¾J²Õ¡A¨ä¥­§¡¨C¤é±Æ¤H³J¤¤ªºÁx©T¾J¶q¬Ûªñ¡Cºî¦X¥H¤W¤§µ²½×¥iª¾¡A§Q¥Î¿ò¶Ç¿ï©Þªº¤èªk¨Ó­°§C³J¶ÀªºÁx©T¾J¡AÁö¦³¥\®Ä¡A¦ý¤@¯ë¥u¥i­°§C¨äÃä»Ú§t¶q¦Ó¤w¡A¦Ó¥B«Ü¥i¯à¤Þ°_²£³J²v¤U­°©Î³J¶ÀÅܤpªº²{¶H¡A¦b¹ê»ÚÀ³¥Î¤W¦ü¥G¨ü¨ì¬Û·í¤jªº­­¨î¡C

        (¤G)Àç¾i§@¥Î(Nutrient effects)

        1. ¹}³Áx©T¾J§t¶q¡G

        ·í¹}³Áx©T¾J§t¶q¼W¥[®É¡A³JÂû¬°ºû«ù¨ä¥¿±`¤§¦åÁx©T¾J¿@«×¡A³q±`·|±NÁx©T¾Jª½±µ±Æ­°¨ì³J¤º¡A¬O¤@ºØ¦³®Äªº¤è¦¡¡A¦P®É¥ç·|¸g¥Ñ¦^õX§@¥Î¾÷¨î¡A­°§CÅ餺Áx©T¾Jªº¥Í¦X¦¨¡A¨Ã¼W¥[¥ÑÁT«K±Æ¥X¤§¤¤©Ê©T¾Jªº¶qHarris and Wilcox(1963)¨Ã«ü¥X¡A·í¹}³ªºÁx©T¾J§t¶q¦b1¢H¥H¤W®É¡A«h¦å²M©M§Z¶À¤¤ªºÁx©T¾J§t¶q§¡¤£¦A©úÅã¼W¥[¡A¥i¯à¬OÁx©T¾Jªº§l¦¬³t²v¤U­°©Ò­P¡CNaber et al., (1985)¤ÎVargas et al., (1986)§Q¥Î®ñ¤Æ©ÊÁx©T¾J­l¥Íª«(Oxygenated cholesterol derivatuies)¬ã¨s¨ä§í¨îHMG-CoA reductaseªº¬¡©Ê¡A¥H§í¨îÁx©T¾Jªº¦X¦¨¡A¨äµ²ªGÅã¥Ü¡AÁx©T¾J¦b¨x¤¤ªº¦X¦¨¶q½T¹ê¨ü¨ì§í¨î¡A¦ý¤£¼vÅT¨ìÁx©T¾J¨I¿n¨ì§Z¶À¤ºªº¶q¡Cºî¦X¥H¤Wµ²ªG«ü¥X¡A³JÂû³q±`¦³¯à¤O¥h¦X¦¨¶W¹L»Ý­n¶qªºÁx©T¾J¡A¨Ã±N¶W¹L»Ý­n¶q¤§Áx©T¾J¨I¿n¨ì§Z¶À¤º¡C

        2. ¹}³¯×ªÕ«¬ºA©M§t¶q

        ³JÂû¹ï¹}³¤¤Áx©T¾Jªº§l¦¬¨ü¨ì¹}³¤¤ªo¯×ªº©Ê½è©Ò¼vÅT¡AWeiss et al., (1967)§Q¥Î°ª¶qªº¤£¹¡©M¤Î¹}©M¯×ªÕ»ÄÁý¹}Âû°¦¡Aµ²ªG(ªí4)Åã¥Ü¡A°ª«×¤£¹¡©Mªo¯×¡A¥i­°§C¦å¤¤Áx©T¾J¡A¹ï³J¶ÀÁx©T¾Jªº§l¦¬«h¦³¨ó¦P§@¥Î¡A¥¦¥i¤U­°¨x¤ºªº¯×ªÕ·s¥Í¦¨§@¥Î¡A¦Ó´£°ªÁx©T¾Jªº¦X¦¨¡A¦ý¬°±Æ­°¦h¾lªºÁx©T¾J¡A¬G±N¨ä¨I¿n¨ì§Z¶À¤¤¡C¹¡©M¯×ªÕ»Ä«h¨ä¦å²G©M§Z¶ÀªºÁx©T¾J³£§e¼W¥[ª¬ºA¡A¦ý¨ä¨x¤¤¦X¦¨Áx©T¾Jªº³t²v¸ûºC¡A¬G¨ä§Z¶À¤¤Áx©T¾J§t¶q¥ç¸û¤Ö¡CHirata et al., (1986)Áý¤©³JÂû¶À¨§ªo¡B·¦¤lªo¡B½Þªo©M¤ûªo¡Aµ²ªGÅã¥Ü³J¶À¤ºªºÁx©T¾J¶q¨ÃµLÅãµÛ®t²§¡A¦ý§Z¶À¤º¯×ªÕ»Äªº²Õ¦¨«h©úÅã¨ü¨ì¼vÅT¡C

ªí4. ¹}³¯×ªÕ¹ï¦å¼ß©M§Z¶ÀÁx©T¾J§t¶qªº¼vÅT

³B²z²Õ¤§¹}³¯×ªÕ§t¶q©M«¬ºA ¦å¼ßÁx©T¾J §Z¶ÀÁx©T¾J
¤§«e ¤§«á §ïÅÜ ¤§«e ¤§«á §ïÅÜ
¡@ mg¡þdl(¢H) (mg¡þg§Z¶À)(¢H)
¸ÕÅç¤@

30¢H¬õªáªo(SO)

30¢H²B¤ÆSO

30¢H·¦¤lªo

30¢H°Êª«¯×ªÕ

¡@

133

128

144

155

¡@

111

158

228

189

¡@

-17

+23

+58

+22

¡@

13.0

13.1

12.1

12.7

¡@

15.6

17.0

14.9

13.7

¡@

+20

+31

+23

+8

¸ÕÅç¤G

§C¯×ªÕ¹ï·Ó²Õ

7.5¢HSO

15¢HSO

30¢HSO

¡@

110

125

124

122

¡@

114

121

89

91

¡@

+4

-3

-28

-25

¡@

11.9

12.2

12.5

11.6

¡@

12.5

12.3

12.5

13.7

¡@

+5

+1

0

+15

ºK¦ÛWeiss et al., (1967)

        3. ¹}³ÅÖºû§t¶q

        ¦³³\¦hªº¬ã¨s¥H´£°ª¹}³ÅÖºûªº¤è¦¡¨Ó´ú©w­°§C¦å¤¤¡B²Õ´©M§Z¶ÀÁx©T¾J§t¶q¡A¦ý¨äµ²ªG¨Ã¤£¤@­P¡AÅÖºû¥i­°§CÁx©T¾Jªº­ì¦]­p¦³(1)­°§CÁx©T¾Jªº§l¦¬¡A(2)»P¸z¹D¤ºªºÁx»Äµ²¦X¡A(3)ÁYµu­¹ª«³q¹L¸z¹Dªº®É¶¡¡A(4)¼W¥[ÁT«K¤¤¤¤©ÊÁx©T¾Jªº±Æªnµ¥§@¥Î¡CMcNaughtom(1978)§Q¥Î¸ªªá¬ó³v¯Å²K¥[¡A¨Ï¨äÅÖºû§t¶q¤À§O¬°2.05¡B4.41¡B6.68©M8.79¢H¡A¦ý¹}³¯à¶q©M´á§t¶q«h¬Ûµ¥¡Aµ²ªGÅã¥Ü(ªí5)¡AÅÖºû§t¶q¹ï²£³J²v©M³J¶À¨S¦³ÅãµÛªº¼vÅT¡A¦ý§Z¶ÀªºÁx©T¾J§t¶q«h¤U­°4~13¢H¡ATuck and Barnett(1972)µo²{­`½¶²K¥[¥iÅãµÛ­°§C±Ä­¹¥É¦Ì¤@¤j¨§²Ë¹}³Âû°¦¤§Áx©T¾J§t¶q¡A¦ý¥¦¤]·|¤Þ°_³J­«¡B±Ä­¹¶q©M²£³J²v¤U­°ªº²{¶H¡A¦ÓÅÖºû¯À«h¶È»´·L´î§C§Z¶À¤§Áx©T¾J¶q¡C¦ÓÅÖºû«h¶È»´·L´î§C§Z¶À¤§Áx©T¾J¶q¡C¦ÓMerge et al., (1974)«h«ü¥X·í¹}³ÅÖºû¶q¥HÅÖºû¯À½Õ¾ã¥Ñ4.1¢H½Õ¾ã¨ì17¢H®É¡A¦å²M¤§Áx©T¾J§t¶q­°§C¡A¦ý§Z¶À¤§Áx©T¾J«h¼W¥[¡A¦Ó³J­«¤Î²£³J²v¥ç­°§C¡CWeiss and Scott(1979)¤ñ¸û¤j¶qªº¾¢¥Ö¡B¿P³Á´ß©M­`½¶¯»¹ïÁx©T¾Jªº¼vÅT¡Aµ²ªGµo²{¡A­`½¶¯»¦³ÅãµÛ­°§C¦å¤¤Áx©T¾Jªº§@¥Î¡A¦ý¤TªÌ¹ï­°§C³J¤¤¤§Áx©T¾J§t¶q«h¤£ÅãµÛ¡CVargas and Naber(1984)¬°¤FÀË°Q¤W­z¦U³ø§i¶¡ªº¥Ù¬Þ²{¶H¡A±´°Q¤FÅÖºû¡BÀç¾i¿@«×©M±Ä­¹¶q¹ï§Z¶ÀÁx©T¾Jªº¼vÅT¡Aµ²ªG«ü¥X¡A·í¦b²£³J²v¥i¥Hºû«ùªº±¡ªp¤U¡AÅÖºû§t¶q¹ï§Z¶ÀÁx©T¾Jªº§t¶q¨S¦³ÅãµÛ¼vÅT¡A¦Ó§Z¶ÀÁx©T¾J§t¶q«h»P¯à¶q¥­¿Å¦³ÅãµÛ¬ÛÃö¡A­YÅ餺ªº¯à¶q¥i¥H¶J¦s®É(7380 Kcal¡þ¤Ñ)¡A«h¹L¦hªº¯à¶q¡A±N³Q¥Î©óÅé­«ªº¼W¥[¡A¦Ó³y¦¨Áx©T¾J¥Í¦¨¼W¥[¡A¹L¦hªºÁx©T¾J¥u¦n±Æ­°¤J³J¤¤¡A¬G§Z¶ÀÁx©T¾J¶q¼W¥[¡C¦Ó·í¯à¶q±Ä­¹§C©ó340Kcal¡þ¤Ñ®É¡A«hÅé­«¤U­°¡A¦ý³J¤ºªºÁx©T¾J§t¶q¨Ã¨S¦³´î§C¡A¬G³o®Éªº§Z¶À¤ºÁx©T¾J«h»PÅé­«§e­t¬ÛÃö¡Cºî¦X¤U­±¤§³ø§i¥iª¾¡AÅÖºû¦³¥i¯à·|­°§C³J¶À¤§Áx©T¾J¶q¡A¦ý»Ýª`·N¨ä¯à¶q¤§½Õ°t»PÂû°¦¤§¤é±Ä­¹¶q¡A§_«h·¥©ö¼vÅT³J­«¤Î²£³J²v¡F¸g¥Ñ¹}³ÅÖºû§t¶qªº½Õ¾ã¡AÁö¥i­°§C§Z¶À¤§Áx©T¾J¹F10¢H¥ª¥k¡A¦ý¤´¤£¨ã¦³°Ó·~»ù­È¡C

ªí5. ³JÂûÁý¤©¤£¦PÅÖºû§t¶q¹}³¹ï²£³J¡B§Z¶À­«©M§Z¶ÀÁx©T¾J§t¶qªº¼vÅT

²ÊÅÖºû(¢H) ²£³J²v(¢H) ³J­«(g) §Z¶À­«(g) §Z¶ÀÁx©T¾J
§t¶q

(mg¡þg§Z¶À)

§ïÅÜ

(¢H)

2.05 78.26 59.5 20.06 14.17a ¡@
4.41 77.08 59.4 19.74 13.75ab -4.39
6.68 77.08 59.2 19.56 13.33b -10.38
8.79 77.17 59.1 19.48 12.62c -13.29

ºK¦ÛMcNaughton(1978).

        4. ¨ä¥L·L¶qÀç¾i

        Constantin and Neagu(1983)µ¹¤©³JÂû¤fªAºû¥Í¯ÀC 0.025¡B0.05©Î0.1g¡Aµ²ªGµo²{¥i­°§C¦å²GÁx©T¾J§t¶q¡A¦ý·|ÀHµÛ¤fªA¾¯¶q¦Ó¼W¥[§Z¶À¤¤ªºÁx©T¾J§t¶q¡CWeiss et al., (1967)©MSingh(1972)µo²{µÒÆP»Ä¥çµL­°§C§Z¤¤Áx©T¾Jªº®ÄªG¡C¥t¥~¨ä¥L¦pºû¥Í¯ÀA¤Î¤@¨Ç¥Íª«µÑ¨ú²G©Î¤u·~¦X¦¨²£«~(Trichoderma virida©MDi-(2-ethyl hexyl)phthalate¡A¥ç³£µLªkÅãµÛ­°§C§Z¶À¤§Áx©T¾J¶q¡C

        5. ¤HÃþ¤§­°¦åÁx©T¾JÃĪ«

        D-isomer thyroxin¥D­n¦b´£ª@Áx©T¾Jªº§ó·s³t²v¡Aµ²ªG³y¦¨¦å²GÁx©T¾J¶q¤U­°¡A¦ý§Z¶ÀÁx©T¾J¤W¤É¡A¦]¬°Âû³J´£¨Ñ¤FÁx©T¾J³Ì¨Îªº±Æªn³~®|¡CTriparanol¬O¤@ºØÁx©T¾J¦X¦¨ªº§í¨î¾¯¡AÅýDesmosterolµLªkÁ٭쬰Áx©T¾J¡A¦ýDesmosterolµLªk¨ú¥NÁx©T¾Jªº¥Í²z¥\¯à¡Aµ²ªG³y¦¨Âû°¦¤§§ZµLªk¦¨¼ô¡A¦Ó³y¦¨§Z±_µäÁY¤Î°±²£¡C¥t¨ä¥L¦pAzasterol compound¡BProbucol¡BLavostatin¡BDichloroacetateµ¥¡A¦³ªºÁö¦³­°§C§Z¶ÀÁx©T¾Jªº®ÄªG¡A¦ý©Ò¯à­°§Cªº¶q³£¦³­­(2~12¢H)¦Ó¥B¨ä¨Ï¥Î«á¡A¬O§_¤Þ°_³J¤ºÃĪ«¤§´Ý¯d¡A³£©|¥¼¸gÃÒ¹ê¡A¬G¤´¤£¨ã°Ó·~¤§¹ê¥Î©Ê(Hargis, 1988)¡C

        Á`¦X¥H¤W¤§¦UÂI¥iª¾¡A±ý¸g¥Ñ¿ò¶Ç¿ï©Þ¡AÀç¾i½Õ¾ã©ÎÃĪ«ªº¨Ï¥Î¡A¥H¶i¦æ§Z¶ÀÁx©T¾J§t¶qªº½Õ±±¡A¦ü¥G³£¥i¦æ¡A¦ý«o³£«ÜÃø­°§C«Ü¦h§Z¶À¤ºªºÁx©T¾J§t¶q¡A¦Ó¦p»P¨C¤é¤§±ÀÂ˶q300mg¬Û¤ñ¡A¦p¤£¯à­°§C§Z¶ÀÁx©T¾J§t¶qªº¤@¥b(100~150mg¡þ³J)¡A«h³£¤£¨ã¦³°Ó·~»ù­È¤Î§Q¯q¡C¥¼¨Ó¤§¬ã¨s¤è¦VÀ³´Â±´°QÁx©T¾J¨I¿n©ó§Z¶Àªº½Õ¸`¾÷¨î¡A¨Ã¸g¥Ñ¾Þ±±¦¹¾÷¨î¨Ó­°§C§Z¶ÀÁx©T¾J¿@«×¦Ó¤£­P¼vÅT²£³J¥Í²z¡C¥Ñ§Z¶À§Î¦¨¤§¥Í²z¬ã¨sµo²{¡A§Z¶À¥ý½è¤¤ªºVLDL¥¼³Q¤À¸Ñ¦Ó¥i§¹¾ã¦a¶i¤J§Z¥À²Ó­M¡A¬G§Z¶ÀªºÁx©T¾J§t¶q¨ú¨M©óVLDLªºÁx©T¾J§t¶q¡C§Z¶À¥ý½èVLDL»PVitellogtuin(VTG)¦@¦PÄvª§§Z¥À²Ó­M½¤¤WªºVLDL¡þVTG±µ¨üÅé¡A¬G¥¼¨Ó­°§C§Z¶ÀÁx©T¾Jªº¨ä¥L¥i¯à³~®|¬°§ïÅܦå¼ß¤¤VTG»PVLDL¤ñ¨Ò¡A¼W¥[VTG¨Ã­°§CVLDL¶i¤J§Z¥À²Ó­Mªº¶q¡A·í¥i´î¤Ö§Z¶ÀªºÁx©T¾J¶q¡A¦ý¤´¦³«Ý¦U¬É¥¼¨Ó«ùÄòªº²`¤J¬ã¨s¡C

¤­¡B°·±d³Jªº¥Í²£

        ºî¦X«e­±©Ò­z¡AÁx©T¾J¬O³y¦¨«aª¬°Ê¯ß¤ßŦ¯fªº¥D¦]¤§¤@¡A¦ýÂû³J¤§Áx©T¾J§t¶q«o«ÜÃø¥[¥H­°§C¡A¦bª`­«®ø¶OªÌ°·±d¶¼­¹ªº·NÃѤU¡A½Õ¾ã¿¯­¹ªº¯×ªÕ»Ä²Õ¦¨¡A¤wÃÒ¹ê¬O´£ª@³J«~ªþ¥[»ù­Èªº¥i¦æ¤èªk¤§¤@¡A¦Ó¥B«Ü¥i³ßªº¬OCruick-shank©ó1934¦~§Y´£¥X(1)¹}³¹ï§Z¶À¤§¯×ªÕ§t¶qÅܤƼvÅT»´·L¡A(2)§Z¶Àªo¤¤¯×ªÕ»Ä²Õ¦¨©ö¨ü¹}³¤§§ïÅÜ¡A(3)¹}³¤¤°ª¤£¹¡©M¯×ªÕ»Ä¼vÅT§Z¶Àªo¤§¯×ªÕ»Ä²Õ¦¨¡A¦ý¹}³¤¤¹¡©M¯×ªÕ»Äªº¼vÅT«h¤£¤j(Hargis, 1994)¡C¥Ø«eªº³\¦h¬ã¨sÅã¥Ü¡A¤HÃþÀç¾i¾Ç®a©MÂå¥Í«Øij¤H­Ì­nÁקK«aª¬°Ê¯ß¤ßŦ¯fªº¦MÀI¡AÀ³­n¦hÄá¨úw-3¯×ªÕ»Ä(w-3 FATTY ACID)¡A¦]¬°¦bw-3¯×ªÕ»Äªº¥NÁ¹Lµ{¤¤·|²£¥ÍÃþªá¥Í»Ä(eicosanoids)¡A¥¦·|¤j¶q´î¤Ö¤HÃþ»¤µo¤ßŦ¯fªº¾÷·|¡Cw-6¯×ªÕ»Ä¥ç·|²£¥ÍÃþªá¥Í»Ä¡A¦ý¥¦«o¬O¤Þ°_¦åºÞ¯fÅܪº¥D¦]¡A©Ò¥H¦b±ÀÂ˪º¹}³¯×ªÕ²Õ¦¨®É¡A³q±`«Øijw-6©Mw-3¯×ªÕ»Äªº²V¦X¤ñÀ³¤p©ó4¡G1¡A¥H¹w¨¾¤ßŦ¦åºÞ¯e¯f¡C°Êª«¦b¹}¤©°ªw-3¯×ªÕ»Ä®É¡A·|­°§C¨ä²Õ´©M²£«~¤¤ªºw-6¯×ªÕ»Ä¶q¡Cªá¥Í¥|²m»Ä(eicosapentaenoic acid, C20¡G5  w-3¡FEPA)©Mªá¥Í¥|²m»ÄAA(arachidonic acid, C20¡G4   w-6¡FAA)¦b¥NÁ¹Lµ{¤¤³£¥i³Q®ñ¤Æ¦¨Ãþªá¥Í»Ä¡A¦ý°ªw-6¡Gw-3¤ñ²v¡A«h·|¨Ï±oªá¥Í¥|²m»ÄAAªº²£¥Í¶q°ª¡A¦Ó§í¨î¤Fw-3¯×ªÕ»Ä§Î¦¨Ãþªá¥Í»Äªº¶q¡A¦Ó¥B¤]§í¨î¤FC18¡G3(¨È³Â¤¯ªo»Ä)¥[ªøºÒÃì¥H§Î¦¨EPA¡Bdocosapentaeonic acid(C22¡G5, w-3¡FDPA)©Mdocosahexaenoic acid(C22¡G6, w-3¡FDHA)¡C¬°¤F­n´£°ªw-3¯×ªÕ»ÄªºÄá¨ú¡A¤HÃþÀç¾i¾Ç®a©MÂå¥Í­Ì³q±`«Øij¤H­Ì¨C¶g¦Ü¤Ö­n¦Y¨âÀ\³½¡A¥H¹w¨¾¤ßŦ¯f¡F¦pªG¯à±Nw-3¯×ªÕ»Äª½±µÁý¤©³JÂû¡A¦Ó¨ÏÂû³J¤º¦³Â×´I¤§w-3¯×ªÕ»Ä¡A¤@¤è­±¤£¶È¦³§U©ó§ïÅÜ¥H©¹¤§³J¬OÁx©T¾J¥D­n¨Ó·½¤§ÅU¼{¡A¦P®É¤S¥i«P¶i³JÃþ¤§®ø¶O¡A©ó¬O°·±d³J¤§¥Í²£¤DÀ³¹B¦Ó¥Í¡C¥Ø«eÀ³¥Î©ó¥Í²£°·±d³J¤§¯×ªÕ»Ä¥D­n¦³DHA¡BEPA©M¨È³Â¤¯ªo»Ä(linolenic acid, C18¡G3  w-3)¡CDHA©MEPA¦b³½ªo¤¤¬Û·íÂ×´I¡A­n¥Í²£°ª¶q¤§EPA©ÎDHAªº°·±d³J¡A³JÂû¹}³¤¤¥i¥[¤J³½ªo©Î°ª¶q³½¯»¨Ó¹F¦¨¡A¦ý¨ä²£«~¤@¯ë¸û©ö¦³³½¸{¨ý(fishy taste)¡C¨È³Â¤¯ªo»Ä³q±`¦s©ó´Óª«²Õ´¤¤¡A¤@¯ë¨S¦³¤Ó³Q±j½Õ¡A·í¹}³§t¦³°ª¶q¤§¨È³Â¤¯ªo»Ä®É¡A³JÂû¨ã¦³¿W¯S¯à¤O±N¼W¥[ªº¨È³Â¤¯ªo»Ä²¾¤J³J¤º¡C¹}®Æ­ì®Æ¤¤ªº¨È³Â(flax)§tÂ×´Iªº¨È³Â¤¯ªo»Ä¡AÁý¤©¨È³Â¬óªº³JÂû¡A¨ä³J¤¤¨È³Â¤¯ªo»Ä§t¶q·|ÅãµÛ¼W¥[¡A¨Ã¥i­°§C¹¡©M¯×ªÕ»Ä§t¶q¡A¦ýÁý¤©30¢Hªº¨È³Â¬ó¡A¹ï³JÂû¤§²£³J¨ã¦³¤£¨}°Æ§@¥Î¡A¤´«Ý¶i¤@¨Bªº¥[¥H§JªA(Leeson and Summer, 1991)¡C(85¦~¹}®Æ·sª¾¬ã°Q·|)

¹}®ÆÀç¾iÂø»x(p.19¡ã32)¢w¿c¥@­õ¡B¤E¤»¦~²Ä¥|´Á